Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 2
Submit an article Journal homepage
1,833
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study

Hareth Nahia Karolinska Institute, Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm, SwedenCorrespondence[email protected]
View further author information
,
Saad Z. Usmanib Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Maria-Victoria Mateosc University Hospital of Salamanca/IBSAL/Cancer Research Center – IBMCC (USAL-CSIC), Salamanca, SpainORCID Iconhttps://orcid.org/0000-0003-2390-1218View further author information
ORCID Icon,
Niels W. C. J. van de Donkd Department of Hematology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The NetherlandsView further author information
,
Albert Oriole Institut Català d‘Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, SpainView further author information
,
Torben Plesnerf Vejle Hospital and University of Southern Denmark, Vejle, DenmarkView further author information
,
Nibedita Bandyopadhyayg Janssen Research & Development, LLC, Spring House, PA, USAView further author information
,
Peter Hellemansh Janssen Research & Development, Beerse, BelgiumView further author information
,
Brenda Trompi Janssen Research & Development, LLC, Leiden, The NetherlandsView further author information
,
Ivo Nnaneg Janssen Research & Development, LLC, Spring House, PA, USAView further author information
,
Donna Zemlickisj Janssen Research & Development, LLC, Toronto, Ontario, CanadaView further author information
,
Ajai Charik Icahn School of Medicine at Mount Sinai, New York, NY, USAORCID Iconhttps://orcid.org/0000-0002-0405-7480View further author information
ORCID Icon &
Philippe Moreaul Hematology Department, University Hospital Hôtel-Dieu, Nantes, FranceView further author information
 show all
Pages 468-472 | Received 15 Jul 2022, Accepted 05 Nov 2022, Published online: 02 Jan 2023

References

  • DARZALEX® (daratumumab) injection [package insert]. Horsham, PA: Janssen Biotech, Inc; 2022.
  • DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) [package insert]. Horsham, PA: Janssen Biotech, Inc; January 2022.
  • San-Miguel J, Usmani SZ, Mateos MV, et al. Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO). Haematologica. 2021;106(6):1725–1732.
  • Usmani SZ, Nahi H, Mateos MV, et al. Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma. Blood. 2019;134(8):668–677.
  • Usmani SZ, Weiss BM, Plesner T, et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 2016;128(1):37–44.
  • Arbour KC, Mezquita L, Long N, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol. 2018;36(28):2872–2878.
  • Namuduri M, Brentjens RJ. Medical management of side effects related to CAR T cell therapy in hematologic malignancies. Expert Rev Hematol. 2016;9(6):511–513.
  • Strati P, Ahmed S, Furqan F, et al. Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Blood. 2021;137(23):3272–3276.
  • Kauer J, Horner S, Osburg L, et al. Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies. J Immunother Cancer. 2020;8(1):e000621.
  • Parsons JA, Greenspan NR, Baker NA, et al. Treatment preferences of patients with relapsed and refractory multiple myeloma: a qualitative study. BMC Cancer. 2019;19(1):264.
  • Durie BGM, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467–1473.
  • Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the international myeloma workshop consensus panel 1. Blood. 2011;117(18):4691–4695.
  • Burwick N, Sharma S. Glucocorticoids in multiple myeloma: past, present, and future. Ann Hematol. 2019;98(1):19–28.
  • Larocca A, Bonello F, Gaidano G, et al. Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit, newly diagnosed multiple myeloma patients. Blood. 2021;137(22):3027–3036.
  • Mateos MV, Nahi H, Legiec W, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol. 2020;7(5):e370–e380.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.